During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
ca.investing.com on MSN7h
BioNTech shares slip as FDA places partial clinical hold on lung cancer studyBioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
After lung cancer, breast cancer is the number two fatal disease for American women. But men are also subject to breast cancer. According to the American Cancer Society, in 2024, nearly 370,000 women ...
A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...
Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback